Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review.
Cinacalcet
Humoral hypercalcemia of malignancy
Pathophysiology
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
16
01
2020
accepted:
21
01
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
21
4
2020
Statut:
epublish
Résumé
Hypercalcemia is an ominous development in the course of malignancy associated with a mean survival of only several months. A majority of cases of hypercalcemia are related to humoral hypercalcemia of malignancy (HHM), where hypercalcemia is caused by increased levels of circulating parathyroid hormone-related protein (PTHrP). Mainstay treatments in the management of HHM are intravenous fluids, intravenous bisphosphonates, and subcutaneous denosumab, although hypercalcemia oftentimes recurs despite these efforts. We present a case of advanced non-small cell lung cancer with PTHrP-mediated hypercalcemia that proved resistant to standard therapy. A trial of oral cinacalcet was initiated and improved calcium levels for 2 months despite a progressive rise in PTHrP and prior to subsequent disease progression. Based on the current body of literature, we propose that this calcium-lowering effect of cinacalcet occurs due to a potential effect on renal calcium excretion.
Identifiants
pubmed: 32308599
doi: 10.1159/000506100
pii: cro-0013-0321
pmc: PMC7154241
doi:
Types de publication
Case Reports
Langues
eng
Pagination
321-329Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
J Clin Oncol. 2001 Jan 15;19(2):558-67
pubmed: 11208851
Curr Opin Nephrol Hypertens. 2013 Jul;22(4):371-6
pubmed: 23736839
J Clin Endocrinol Metab. 2014 Sep;99(9):3144-52
pubmed: 24915117
J Clin Invest. 2003 Dec;112(12):1906-14
pubmed: 14679186
Clin Cancer Res. 2005 Jun 1;11(11):4198-203
pubmed: 15930357
Ther Clin Risk Manag. 2015 Dec 04;11:1779-88
pubmed: 26675713
Cold Spring Harb Perspect Med. 2018 Aug 1;8(8):
pubmed: 29358318
J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9
pubmed: 12679445
Am J Physiol Endocrinol Metab. 2009 Oct;297(4):E915-23
pubmed: 19797241
Electrolyte Blood Press. 2008 Dec;6(2):68-76
pubmed: 24459525
J Clin Endocrinol Metab. 2001 Apr;86(4):1525-31
pubmed: 11297578
Endocrinol Diabetes Metab Case Rep. 2017 Dec 15;2017:
pubmed: 29399364
CA Cancer J Clin. 2018 Sep;68(5):377-386
pubmed: 30240520
Nat Rev Endocrinol. 2015 May;11(5):298-307
pubmed: 25752283
Case Rep Oncol. 2012 Jan;5(1):1-8
pubmed: 22379470
Orphanet J Rare Dis. 2017 Jan 25;12(1):19
pubmed: 28122587
Curr Pharm Biotechnol. 2009 Apr;10(3):302-10
pubmed: 19355940